Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Originator

Pelletier, J.|Caventou, J.

6

Pfizer

420

Eli Lilly

239

Merck

238

GlaxoSmithKline

197

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Previously Marketed

4

Other

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

neurotransmitter secretion

4

voltage-gated sodium channel activity

4

Glycine receptor (alpha-1/beta)

2

Glycine receptor subunit alpha-1

2

LoVo

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Not Provided

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1921

4

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Hypertension

4

Aplastic anemia

2

Glioma

2

Multiple myeloma

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

6

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

EPA CompTox

4

MERCK INDEX

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

BRUCINE

6NG17YCK6H

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

T cell proliferation

Vascular endothelial growth factor receptor 2

Glycine receptor (alpha-1/beta)

Glycine receptor subunit alpha-1

Conditions:

Aplastic anemia

Multiple myeloma

Brucine is an alkaloid resembling strychnine but it is much less potent than strychnine. Brucine was first discovered in 1819 by Pelletier and Caventou in the bark of the Strychnos nux vomica tree. Brucine causes paralysis of the peripheral nerve end...

ings and produces violent convulsions. Since brucine is a large chiral molecule, it has been used as an enantioselective recognition agent using in chiral resolution. While brucine has been shown to have good anti-tumor effects, on both hepatocellular carcinoma and breast cancer, its narrow therapeutic window has limited its use as a treatment for cancer. Brucine is also used in traditional Chinese medicine as an anti-inflammatory and analgesic agent, as well as in some Ayurveda and homeopathy drugs. Like strychnine, brucine also functions as antagonist at the glycine receptor and paralyzes the inhibitory neurons

CEVADINE

ERQ7M6C50B

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

voltage-gated sodium channel activity

neurotransmitter secretion

Conditions:

Cevadine, veratridine, and related lipophilic ceveratrum alkaloids cause activation of the voltage-sensitive Na+ channels of nerve, heart, and skeletal muscle cell membranes similar to pyrethrins. Both veratridine and cevadine alter the ion selectivi...

ty of Na+ channels and cause persistent activation. The receptor for these alkaloids has not been isolated, but experiments indicate it is distinct from that of pyrethrin. Structurally, veratridine and cevadine differ only in their acyl group. Cevadine has been used as an insecticide, acting as a paralytic agent with higher toxicity to insects than to mammals. It has been used to study Na+ channel blockers such as vincamine and vincanol by inducing Na+ channels in the presence and absence of the drugs being tested.

BRUCINE TETRAHYDRATE

UEJ23QX4RE

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

T cell proliferation

Vascular endothelial growth factor receptor 2

Glycine receptor (alpha-1/beta)

Glycine receptor subunit alpha-1

Conditions:

Aplastic anemia

Multiple myeloma

Brucine is an alkaloid resembling strychnine but it is much less potent than strychnine. Brucine was first discovered in 1819 by Pelletier and Caventou in the bark of the Strychnos nux vomica tree. Brucine causes paralysis of the peripheral nerve end...

ings and produces violent convulsions. Since brucine is a large chiral molecule, it has been used as an enantioselective recognition agent using in chiral resolution. While brucine has been shown to have good anti-tumor effects, on both hepatocellular carcinoma and breast cancer, its narrow therapeutic window has limited its use as a treatment for cancer. Brucine is also used in traditional Chinese medicine as an anti-inflammatory and analgesic agent, as well as in some Ayurveda and homeopathy drugs. Like strychnine, brucine also functions as antagonist at the glycine receptor and paralyzes the inhibitory neurons

CEVADINE ACETATE

4SDI43AD5Q

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

voltage-gated sodium channel activity

neurotransmitter secretion

Conditions:

Cevadine, veratridine, and related lipophilic ceveratrum alkaloids cause activation of the voltage-sensitive Na+ channels of nerve, heart, and skeletal muscle cell membranes similar to pyrethrins. Both veratridine and cevadine alter the ion selectivi...

ty of Na+ channels and cause persistent activation. The receptor for these alkaloids has not been isolated, but experiments indicate it is distinct from that of pyrethrin. Structurally, veratridine and cevadine differ only in their acyl group. Cevadine has been used as an insecticide, acting as a paralytic agent with higher toxicity to insects than to mammals. It has been used to study Na+ channel blockers such as vincamine and vincanol by inducing Na+ channels in the presence and absence of the drugs being tested.

CEVADINE HYDROCHLORIDE

75GK03249U

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

voltage-gated sodium channel activity

neurotransmitter secretion

Conditions:

Cevadine, veratridine, and related lipophilic ceveratrum alkaloids cause activation of the voltage-sensitive Na+ channels of nerve, heart, and skeletal muscle cell membranes similar to pyrethrins. Both veratridine and cevadine alter the ion selectivi...

ty of Na+ channels and cause persistent activation. The receptor for these alkaloids has not been isolated, but experiments indicate it is distinct from that of pyrethrin. Structurally, veratridine and cevadine differ only in their acyl group. Cevadine has been used as an insecticide, acting as a paralytic agent with higher toxicity to insects than to mammals. It has been used to study Na+ channel blockers such as vincamine and vincanol by inducing Na+ channels in the presence and absence of the drugs being tested.

CEVADINE SULFATE

3TU82R4MEV

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1921

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

voltage-gated sodium channel activity

neurotransmitter secretion

Conditions:

Cevadine, veratridine, and related lipophilic ceveratrum alkaloids cause activation of the voltage-sensitive Na+ channels of nerve, heart, and skeletal muscle cell membranes similar to pyrethrins. Both veratridine and cevadine alter the ion selectivi...

ty of Na+ channels and cause persistent activation. The receptor for these alkaloids has not been isolated, but experiments indicate it is distinct from that of pyrethrin. Structurally, veratridine and cevadine differ only in their acyl group. Cevadine has been used as an insecticide, acting as a paralytic agent with higher toxicity to insects than to mammals. It has been used to study Na+ channel blockers such as vincamine and vincanol by inducing Na+ channels in the presence and absence of the drugs being tested.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1